Forman stated that the Department would be focused on: (i) “potential antitrust enforcement on private equity ‘roll-ups,’ namely, whether in particular circumstances a series of often smaller transactions can cumulatively or otherwise lead to a substantial lessening of competition or tendency to create a monopoly;” (ii) “whether certain private equity investments may either blunt the incentive of the target company to act as a maverick or a disruptor in health care… [read post]